Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Medtronic
Dow
Harvard Business School
Mallinckrodt

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,258,098

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,258,098
Title:Antitumoral treatments
Abstract: The present invention relates to combinations of aplidine or aplidine analogues with other titumoral agents, and the use of these combinations in the treatment of cancer, in particular in the treatment of lung cancer, breast cancer, colon cancer, prostate cancer, renal cancer, melanoma, multiple myeloma, leukemia and lymphoma.
Inventor(s): Faircloth; Glynn Thomas (Cambridge, MA), Aviles Marin; Pablo Manuel (Madrid, ES), LePage; Doreen (Cambridge, MA), Izquierdo; Jesus San Miguel (Salamanca, ES), Pandiella; Atanasio (Salamanca, ES)
Assignee: Pharma Mar, S.A. (Madrid, ES)
Application Number:12/278,559
Patent Claims:1. A method of treating a cancer selected from breast cancer, prostate cancer, colon cancer, lung cancer, multiple myeloma, and melanoma, comprising administering to a patient in need of such treatment a therapeutically effective amount of aplidine and a therapeutically effective amount of another drug, wherein said drug is selected from paclitaxel, cisplatin, arsenic trioxide, 5-fluorouracil, carboplatin, 7-ethyl-10-hydroxycamptothecin, etoposide, melphalan, dexamethasone, bortezomib, lenalidomide, idarubicin, and rituximab, and wherein said amounts of both drugs together provide a synergistic effect.

2. A method of increasing the therapeutic efficacy of a drug effective in the treatment of a cancer selected from breast cancer, prostate cancer, colon cancer, lung cancer, multiple myeloma, and melanoma, wherein said drug is selected from paclitaxel, cisplatin, arsenic trioxide, 5-fluorouracil, carboplatin, 7-ethyl-10-hydroxycamptothecin, etoposide, melphalan, dexamethasone, bortezomib, lenalidomide, idarubicin, and rituximab, which comprises administering to a patient with said cancer in need thereof said drug and an amount of aplidine, and wherein the amounts of both drugs together provide a synergistic effect.

3. The method according to claim 1, wherein a therapeutically effective amount of a third drug selected from melphalan, dexamethasone, bortezomib, lenalidomide, and thalidomide is administered.

4. The method according to claim 1, wherein said drug is paclitaxel.

5. The method according to claim 1, wherein said drug is cisplatin.

6. The method according to claim 1, wherein said drug is arsenic trioxide.

7. The method according to claim 1, wherein said drug is 5-fluorouracil.

8. The method according to claim 1, wherein said drug is carboplatin.

9. The method according to claim 1, wherein said drug is 7-ethyl-10-hydroxycamptothecin.

10. The method according to claim 1, wherein said drug is etoposide.

11. The method according to claim 1, wherein said drug is melphalan.

12. The method according to claim 1, wherein said drug is dexamethasone.

13. The method according to claim 1, wherein said drug is bortezomib.

14. The method according to claim 1, wherein said drug is lenalidomide.

15. The method according to claim 1, wherein said drug is idarubicin.

16. The method according to claim 1, wherein said drug is rituximab.

17. The method according to any of claims 4, 5 or 7, wherein said method is a method of treating breast cancer.

18. The method according to any of claims 4, 6, 7 or 8, wherein said method is a method of treating prostate cancer.

19. The method according to any one of claims 5, 6, or 8, wherein said method is a method of treating colon cancer.

20. The method according to any one of claims 6, 7 or 9, wherein said method is a method of treating lung cancer.

21. The method according to any one of claims 10 to 14, wherein said method is a method of treating multiple myeloma.

22. The method according to claim 8, wherein said method is a method of treating melanoma.

23. The method according to claim 3, wherein the second drug is lenalidomidc and the third drug is dexamethasone.

24. The method according to claim 3, wherein the second drug is bortezomib and the third drug is dexamethasone.

25. The method according to claim 3, wherein the second drug is bortezomib and the third drug is lenalidomide.

26. The method according to claim 3, wherein the second drug is dexamethasone and the third drug is thalidomide.

27. The method according to claim 3, wherein the second drug is dexamethasone and the third drug is melphalan.

28. The method according to claim 3, wherein the second drug is melphalan and the third drug is bortezomib.

29. The method according to any one of claims 23 to 28, wherein said method is a method of treating multiple myeloma.

Summary for Patent:   Start Trial

PCT Information
PCT FiledFebruary 28, 2007PCT Application Number:PCT/US2007/062936
PCT Publication Date:September 07, 2007PCT Publication Number:WO2007/101235

Details for Patent 8,258,098

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Start Trial Pharma Mar, S.A. (Madrid, ES) 2039-03-29 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Pharma Mar, S.A. (Madrid, ES) 2039-03-29 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Pharma Mar, S.A. (Madrid, ES) 2039-03-29 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,258,098

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2007101235 Apr 03, 2008
World Intellectual Property Organization (WIPO) 2007101235 Sep 07, 2007
United States of America 2009246168 Oct 01, 2009
Slovenia 2029155 Jun 30, 2016
Russian Federation 2008138560 Apr 10, 2010
Russian Federation 2481853 May 20, 2013
Serbia 54928 Oct 31, 2016
>Country >Patent Number >Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Moodys
Express Scripts
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.